Limits...
HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients.

Yang J, Chen J, Ye P, Jin L, Wu W, Sheng G, Li LJ - J Transl Med (2014)

Bottom Line: Furthermore, the positive correlation between HBsAg and ALT, HBV DNA and Treg levels was significant for SC patients, but not for non-SC patients.However, for HBeAg, significant positive correlations were or not observed for both SC and non-SC patients.The quantitation of HBsAg is a more useful indicator than HBeAg for distinguishing SC and non-SC patients during TDF treatment.

View Article: PubMed Central - HTML - PubMed

Affiliation: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. ljli@zju.edu.cn.

ABSTRACT

Background: Serum quantitative hepatitis B surface antigen (HBsAg) levels may be an important predictor of hepatitis B e antigen (HBeAg) seroconversion (SC) in HBeAg-positive chronic hepatitis B (CHB) patients during antiviral treatment. The pattern of HBsAg variation in CHB patients either with or without SC following tenofovir disoproxil fumarate (TDF) treatment is not clearly understood.

Methods: Twenty patients with full experimental data were enrolled, and liver biochemistry, serum HBV DNA, and circulating CD4+CD25+ regulatory T cell (Treg) levels were determined at baseline and every 12 weeks after the initiation of TDF treatment (for a total of 96 weeks). In addition, the relationship between HBsAg or HBeAg and alanine aminotransferase (ALT), HBV DNA and Treg levels in SC and non-SC patients was analyzed.

Results: In all, 9 patients had undergone HBeAg seroconversion by week 72 of TDF treatment, and biochemical and virological indexes and Treg percentages declined to normal levels. Furthermore, the positive correlation between HBsAg and ALT, HBV DNA and Treg levels was significant for SC patients, but not for non-SC patients. However, for HBeAg, significant positive correlations were or not observed for both SC and non-SC patients.

Conclusions: The quantitation of HBsAg is a more useful indicator than HBeAg for distinguishing SC and non-SC patients during TDF treatment. Moreover, HBsAg may be related to immune regulatory property of CHB patients during antiviral treatment.

Show MeSH

Related in: MedlinePlus

Changing characteristic of HBsAg in SC or non-SC patients during treatment. The changing profile of serum HBsAg (log10 IU/ml) level of each patient was classified to SC (A) or non-SC patients (B) during TDF treatment for 96 weeks.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4230803&req=5

Figure 1: Changing characteristic of HBsAg in SC or non-SC patients during treatment. The changing profile of serum HBsAg (log10 IU/ml) level of each patient was classified to SC (A) or non-SC patients (B) during TDF treatment for 96 weeks.

Mentions: We performed longitudinal analysis of HBsAg (log10 IU/ml) in peripheral blood in the SC and non-SC groups during 96 weeks of treatment with TDF. We found that the HBsAg content for each patient consistently declined over the course of 96 weeks of antiviral treatment period in the SC group (Figure 1A), which was different from the pattern of fluctuating decline in HBsAg levels in the non-SC group (Figure 1B). Furthermore, there were no significant differences between the SC and non-SC groups in the mean HBsAg levels at baseline or each treatment time point over the course of 96 weeks (Additional file 1: Figure S1). However, mean HBsAg was significantly different between the baseline and at week 12 in SC patients, but not in the non-SC group (Additional file 2: Figure S2).


HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients.

Yang J, Chen J, Ye P, Jin L, Wu W, Sheng G, Li LJ - J Transl Med (2014)

Changing characteristic of HBsAg in SC or non-SC patients during treatment. The changing profile of serum HBsAg (log10 IU/ml) level of each patient was classified to SC (A) or non-SC patients (B) during TDF treatment for 96 weeks.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4230803&req=5

Figure 1: Changing characteristic of HBsAg in SC or non-SC patients during treatment. The changing profile of serum HBsAg (log10 IU/ml) level of each patient was classified to SC (A) or non-SC patients (B) during TDF treatment for 96 weeks.
Mentions: We performed longitudinal analysis of HBsAg (log10 IU/ml) in peripheral blood in the SC and non-SC groups during 96 weeks of treatment with TDF. We found that the HBsAg content for each patient consistently declined over the course of 96 weeks of antiviral treatment period in the SC group (Figure 1A), which was different from the pattern of fluctuating decline in HBsAg levels in the non-SC group (Figure 1B). Furthermore, there were no significant differences between the SC and non-SC groups in the mean HBsAg levels at baseline or each treatment time point over the course of 96 weeks (Additional file 1: Figure S1). However, mean HBsAg was significantly different between the baseline and at week 12 in SC patients, but not in the non-SC group (Additional file 2: Figure S2).

Bottom Line: Furthermore, the positive correlation between HBsAg and ALT, HBV DNA and Treg levels was significant for SC patients, but not for non-SC patients.However, for HBeAg, significant positive correlations were or not observed for both SC and non-SC patients.The quantitation of HBsAg is a more useful indicator than HBeAg for distinguishing SC and non-SC patients during TDF treatment.

View Article: PubMed Central - HTML - PubMed

Affiliation: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. ljli@zju.edu.cn.

ABSTRACT

Background: Serum quantitative hepatitis B surface antigen (HBsAg) levels may be an important predictor of hepatitis B e antigen (HBeAg) seroconversion (SC) in HBeAg-positive chronic hepatitis B (CHB) patients during antiviral treatment. The pattern of HBsAg variation in CHB patients either with or without SC following tenofovir disoproxil fumarate (TDF) treatment is not clearly understood.

Methods: Twenty patients with full experimental data were enrolled, and liver biochemistry, serum HBV DNA, and circulating CD4+CD25+ regulatory T cell (Treg) levels were determined at baseline and every 12 weeks after the initiation of TDF treatment (for a total of 96 weeks). In addition, the relationship between HBsAg or HBeAg and alanine aminotransferase (ALT), HBV DNA and Treg levels in SC and non-SC patients was analyzed.

Results: In all, 9 patients had undergone HBeAg seroconversion by week 72 of TDF treatment, and biochemical and virological indexes and Treg percentages declined to normal levels. Furthermore, the positive correlation between HBsAg and ALT, HBV DNA and Treg levels was significant for SC patients, but not for non-SC patients. However, for HBeAg, significant positive correlations were or not observed for both SC and non-SC patients.

Conclusions: The quantitation of HBsAg is a more useful indicator than HBeAg for distinguishing SC and non-SC patients during TDF treatment. Moreover, HBsAg may be related to immune regulatory property of CHB patients during antiviral treatment.

Show MeSH
Related in: MedlinePlus